Evidence map›Paper›PMID 42001349›Full record

ArticleDiscover oncology2026

Correlation between E2F7 overexpression and immune infiltration in lung adenocarcinoma.

Xiangting Gao, Chengyi Zhao, Shuyi Wang, Jinxia Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xiangting GaoDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, First Affiliated Hospital, Shihezi University, Shihezi University School of Medicine, 107 North 2nd Road, Shihezi, China. gxt1523628@foxmail.com.
Chengyi ZhaoDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, First Affiliated Hospital, Shihezi University, Shihezi University School of Medicine, 107 North 2nd Road, Shihezi, China.
Shuyi WangDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, First Affiliated Hospital, Shihezi University, Shihezi University School of Medicine, 107 North 2nd Road, Shihezi, China.
Jinxia LiDepartment of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, First Affiliated Hospital, Shihezi University, Shihezi University School of Medicine, 107 North 2nd Road, Shihezi, China.

Funding

Shihezi University ZZZC202137
6 · The paper itself

Abstract

objectiveTo investigate E2F7 expression in lung adenocarcinoma and its link to immune infiltration.

methodsThe mRNA expression levels of E2F7 in lung adenocarcinoma and adjacent non-cancerous tissues were assessed using data from TCGA. Additionally, the mRNA and protein expression levels of E2F7 in lung adenocarcinoma tissues were evaluated through RT-qPCR and immunohistochemistry. The association between E2F7 expression levels and the clinicopathological characteristics of patients was also examined. GO and KEGG analyses were conducted to investigate the genes co-expressed with E2F7 in lung adenocarcinoma within the TCGA database, and their relationships with immune cells and immune checkpoints were analyzed.

resultsE2F7 expression was significantly elevated in lung adenocarcinoma tissues compared to adjacent non-cancerous tissues. Furthermore, high E2F7 expression was significantly associated with poorer prognosis in lung adenocarcinoma patients. Genes co-expressed with E2F7 was predominantly enriched in pathways related to olfactory processes, chemical stimuli, and ligand-receptor interactions involved in neural activity. Furthermore, E2F7 expression is linked to various immune cell types and immune checkpoint pathways.

conclusionE2F7 is significantly upregulated in lung adenocarcinoma tissues and is correlated with poor patient prognosis. Therefore, E2F7 may serve as a potential prognostic biomarker for patients with lung adenocarcinoma.

Indexed as

E2F7Immune infiltrationLung adenocarcinomaPrognosisTCGA database

Identifiers

PMID42001349
PMCPMC13219703

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.